Veracyte, Inc.
VCYT· Nasdaq
VCYTVeracyte, Inc.
Filed Feb 28, 2022 · 10-K · 59 days after period end · 0001384101-22-000028
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $67.34M | $34.54M | $29.73M | $25.75M |
| Net Income | -$10.53M | -$8.04M | -$7.46M | — |
| EPS Diluted | — | -$0.14 | -$0.15 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Veracyte, Inc. · CIK 1384101 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 28, 2022 · 59 d after period end
